Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.
The conversation is about finding high-purity RU58841 solutions for hair loss treatment, with mentions of Anagenic, Selleckchem, MV Supplement, and rudirect.co.uk as potential sources. Users discuss their experiences and preferences regarding product quality and shipping.
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
The user claims to have successfully treated hair loss using natural supplements like collagen, L-lysine, zinc, B12, and bamboo shoot extract, without using the "Big 3" treatments (Minoxidil, finasteride, RU58841). The community is skeptical, demanding proof and emphasizing that the "Big 3" are proven effective, while natural remedies are often not.
Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hair growth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.
A 19-year-old is experiencing hair thinning and considering using RU58841 alongside minoxidil, which initially worked but lost effectiveness. Others advise caution, suggesting safer alternatives like topical finasteride and consulting a doctor before using unapproved treatments like RU58841.
User experienced significant hair regrowth with multiple treatments, but then had a brutal shedding period, losing progress. Others questioned the number of treatments used and potential side effects.
Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.
The 6 month progress of a 40 year old user using topical Finasteride and Minoxidil and weekly Microneedling to treat hair loss, with other users offering advice and asking questions.
A 26-year-old individual treating hair loss since 19, using a regimen of Finasteride, Cyproterone, Oral Minoxidil, Microneedling, Dutasteride, and newly added RU58841. They're seeking advice from other RU58841 users about their experiences.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
The user is experiencing some hair regrowth after six months on oral minoxidil (3mg), finasteride (1.2mg), and using 1% ketoconazole shampoo twice a week, with no side effects. They are advised to consult a doctor before adjusting doses and to consider blood tests for vitamin and mineral levels.
PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.
Microneedling for 6 months with minoxidil showed no improvements in hair growth. User seeks advice on other treatments or whether to continue microneedling; current stack includes finasteride, eucapil, and minoxidil with tretinoin.
The user has been using finasteride for four years and topical minoxidil with microneedling for a year but has not seen significant results in slowing hair loss. They are considering trying dutasteride despite concerns about its intensity, and others suggest trying oral minoxidil or combining treatments for better results.
The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.
A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.
The conversation discusses a hair loss treatment regimen using Alfatradiol, Pyrilutamide, and Minoxidil. The user shares their current stack of these treatments.
A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.
PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.
A user shared their hair loss treatment regimen, which includes minoxidil, finasteride, ketoconazole shampoo, stemoxydine, and microneedling, and reported promising results. Other users complimented the progress.
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
The conversation discusses the tension theory of baldness, suggesting that over-developed masseter muscles may harm hair follicles. Botox injections to relax these muscles reportedly led to an 18% increase in hair count in men with AGA.